False positives more likely in heart disorder genetic testing for black patients

According to a new study, genetic testing is more likely to turn up false positives for black people than white people when looking for mutations related to hypertrophic cardiomyopathy.

According to the New York Times, the discrepancy comes from a lack of diversity in early trials surrounding the testing. There weren’t enough people included belonging to racial and ethnic minority groups, so researchers couldn’t get a full picture of what the mutations might look like in people who weren’t white.

And the cases of mistaken genetic testing could extend beyond this one condition.

The false positives in testing could cause problems for the patients mistakenly believing they have a rare heart disorder, such as emotional trauma and undergoing unnecessary procedures.

Check out the New York Times to see how the mistake could be affecting testing for other disorders and diseases. 

Caitlin Wilson,

Senior Writer

As a Senior Writer at TriMed Media Group, Caitlin covers breaking news across several facets of the healthcare industry for all of TriMed's brands.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.